These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8851208)

  • 21. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity.
    de Jong MD; Loewenthal M; Boucher CA; van der Ende I; Hall D; Schipper P; Imrie A; Weigel HM; Kauffmann RH; Koster R
    J Infect Dis; 1994 Jun; 169(6):1346-50. PubMed ID: 8195615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of circulating p24 antigen-positive CD4+ cells during HIV infection by flow cytometry.
    Costigliola P; Tumietto F; Ricchi E; Chiodo F
    AIDS; 1992 Oct; 6(10):1121-5. PubMed ID: 1361340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of in vivo effect of granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus type 1.
    Scadden DT; Pickus O; Hammer SM; Stretcher B; Bresnahan J; Gere J; McGrath J; Agosti JM
    AIDS Res Hum Retroviruses; 1996 Aug; 12(12):1151-9. PubMed ID: 8844019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.
    O'Brien WA; Hartigan PM; Martin D; Esinhart J; Hill A; Benoit S; Rubin M; Simberkoff MS; Hamilton JD
    N Engl J Med; 1996 Feb; 334(7):426-31. PubMed ID: 8552144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of combined zidovudine and didanosine therapy in early asymptomatic primary HIV-1 infection.
    Khajotia RR; Feigley CE; Lee E; Gu J
    AIDS; 1998 Jan; 12(2):222-4. PubMed ID: 9468376
    [No Abstract]   [Full Text] [Related]  

  • 26. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.
    Meng TC; Fischl MA; Boota AM; Spector SA; Bennett D; Bassiakos Y; Lai SH; Wright B; Richman DD
    Ann Intern Med; 1992 Jan; 116(1):13-20. PubMed ID: 1345755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial.
    Fiscus SA; DeGruttola V; Gupta P; Katzenstein DA; Meyer WA; LoFaro ML; Katzman M; Ragni MV; Reichelderfer PS; Coombs RW
    J Infect Dis; 1995 Feb; 171(2):305-11. PubMed ID: 7844365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring antiretroviral activity using ICDp24 and CD4 counts in HIV infection.
    Lillo FB; Maillard M; Saracco A; Varnier OE
    J Infect; 1997 Jul; 35(1):67-71. PubMed ID: 9279727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term evaluation of zidovudine-treated patients: decrease in plasma and cellular viraemia titres.
    Tamalet C; Masquelier B; Ferchal F; Agut H; Puel J; Brun-Vézinet F; Fleury H; Rouzioux C
    AIDS; 1992 Nov; 6(11):1403-4. PubMed ID: 1361750
    [No Abstract]   [Full Text] [Related]  

  • 30. Resolution of HIV retinitis with zidovudine therapy.
    Molina JM; Ferchal F; Marcel P; Morinet F; Modai J
    Am J Med; 1992 Dec; 93(6):700-2. PubMed ID: 1361303
    [No Abstract]   [Full Text] [Related]  

  • 31. Quantitation of unintegrated HIV-1 DNA in asymptomatic patients in the presence or absence of antiretroviral therapy.
    Bush CE; Donovan RM; Smereck SM; Strang D; Markowitz N; Saravolatz LD
    AIDS Res Hum Retroviruses; 1993 Feb; 9(2):183-7. PubMed ID: 8096146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy.
    Schüpbach J; Böni J; Bisset LR; Tomasik Z; Fischer M; Günthard HF; Ledergerber B; Opravil M;
    J Acquir Immune Defic Syndr; 2003 Jul; 33(3):292-9. PubMed ID: 12843739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study.
    Wood R; Montoya JG; Kundu SK; Schwartz DH; Merigan TC
    J Infect Dis; 1993 Mar; 167(3):519-25. PubMed ID: 8095058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
    Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
    Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).
    Mulder JW; Cooper DA; Mathiesen L; Sandström E; Clumeck N; Gatell JM; French M; Donovan B; Gray F; Yeo JM
    AIDS; 1994 Mar; 8(3):313-21. PubMed ID: 7913326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiviral and immunological effects of escalating low doses of zidovudine in HIV-positive patients.
    Stellbrink HJ; Albrecht H; Plettenberg A; Stoehr A; Laufs R; Fenske S; Greten H
    Eur J Clin Microbiol Infect Dis; 1993 Aug; 12(8):618-21. PubMed ID: 7901017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitation of human immunodeficiency virus (HIV) with respect to disease stage and zidovudine (AZT) therapy.
    Ved Brat SS; Shepherd LP; Boulberhane A; Pierce PF; Hellman KB
    AIDS Res Hum Retroviruses; 1992 Jul; 8(7):1271-81. PubMed ID: 1520539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of plasma viral load in HIV-1 infection by quantitative competitive polymerase chain reaction.
    Piatak M; Saag MS; Yang LC; Clark SJ; Kappes JC; Luk KC; Hahn BH; Shaw GM; Lifson JD
    AIDS; 1993 Nov; 7 Suppl 2():S65-71. PubMed ID: 7909227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of HIV type 1 RNA plasma viremia, p24 antigenemia, and unintegrated DNA as viral load markers in pediatric patients.
    Bush CE; Donovan RM; Manzor O; Baxa D; Moore E; Cohen F; Saravolatz LD
    AIDS Res Hum Retroviruses; 1996 Jan; 12(1):11-5. PubMed ID: 8825613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Differences in detectability of human immunodeficiency virus type 1 in tears and blood lymphocytes].
    Geier SA; Gürtler L; Klauss V; Mueller A; Bader L; Eberle J; Bogner JJ; Kronawitter U; Goebel FD; Lund OE
    Klin Monbl Augenheilkd; 1992 Sep; 201(3):164-8. PubMed ID: 1383601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.